Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024 [Yahoo! Finance]
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
Iterum Therapeutics plc (NASDAQ: ITRM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem [Yahoo! Finance]
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem